Elizabeth A. Griffiths

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Jan Krönke, Emma C. Fink, Paul W. Hollenbach et al. · Nature · 2015 · 816 citations · Full text

Medicine, Cell Death, Pharmacology +2

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2016 · 293 citations

Hematological Malignancy, Oncology, Diagnostic Classification +14

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 280 citations · Full text

Hematological Malignancy, Dose-escalation Phase 1, Oncology +9

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma et al. · Blood · 2020 · 205 citations · Full text